Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 273
Healthy volunteers: yes

Brief summary:
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.

Detailed description:

Arms:
arm 1: sitagliptin 100 mg arm 2: rosiglitazone 8 mg arm 3: placebo

Interventions: intervention 1: Sitagliptin intervention 2: Comparator: Rosiglitazone intervention 3: Comparator: Placebo intervention 4: Comparator: Metformin
Intervention descriptions: intervention 1: Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks. intervention 2: Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks. intervention 3: placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks. intervention 4: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.

Protocol document: